Wellington Management Group LLP Takes $802,000 Position in Trevi Therapeutics, Inc. $TRVI

Wellington Management Group LLP bought a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 127,452 shares of the company's stock, valued at approximately $802,000. Wellington Management Group LLP owned approximately 0.13% of Trevi Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in Trevi Therapeutics in the 4th quarter worth approximately $49,000. Squarepoint Ops LLC purchased a new stake in shares of Trevi Therapeutics during the fourth quarter worth $58,000. Two Sigma Advisers LP bought a new position in shares of Trevi Therapeutics in the fourth quarter worth $66,000. Cantor Fitzgerald L. P. purchased a new position in shares of Trevi Therapeutics in the fourth quarter valued at $82,000. Finally, ProShare Advisors LLC grew its position in shares of Trevi Therapeutics by 86.4% in the fourth quarter. ProShare Advisors LLC now owns 20,685 shares of the company's stock valued at $85,000 after purchasing an additional 9,589 shares in the last quarter. Institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI traded down $0.22 during mid-day trading on Friday, hitting $7.01. The stock had a trading volume of 1,613,444 shares, compared to its average volume of 1,942,515. The business has a 50 day moving average price of $7.07 and a two-hundred day moving average price of $6.37. Trevi Therapeutics, Inc. has a 1 year low of $2.36 and a 1 year high of $8.78. The firm has a market cap of $853.68 million, a P/E ratio of -16.69 and a beta of 0.71.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Equities research analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Cantor Fitzgerald initiated coverage on Trevi Therapeutics in a research note on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 target price for the company. D. Boral Capital restated a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Monday, June 2nd. HC Wainwright assumed coverage on shares of Trevi Therapeutics in a report on Wednesday, May 28th. They set a "buy" rating and a $21.00 target price on the stock. Oppenheimer reiterated an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Finally, Wall Street Zen cut shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to MarketBeat.com, Trevi Therapeutics presently has a consensus rating of "Buy" and an average target price of $20.11.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.